🟢 Strong Evidence
A landmark trial published in Nature Medicine (June 2026) demonstrates that combining perioperative androgen-deprivation therapy (ADT) with the androgen receptor inhibitor apalutamide offers a new treatment pathway for patients with high-risk, localized prostate cancer. The PROTEUS trial, reported online in Nature Medicine, evaluates a therapeutic strategy that bridges medical and surgical oncology approaches for men facing aggressive disease before radical prostatectomy.
Key takeaways
- Perioperative apalutamide combined with androgen-deprivation therapy represents a potential new standard for high-risk, localized prostate cancer
- The PROTEUS trial published in Nature Medicine demonstrates efficacy of neoadjuvant therapy before radical prostatectomy
- This approach integrates medical oncology into the surgical management of aggressive prostate cancer
- Data from Nature Medicine (2026) support earlier intervention to reduce recurrence risk
Study at a Glance
| Source | Nature Medicine |
| Study type | Clinical trial |
| Focus | High-risk, localized prostate cancer |
| Intervention | Perioperative androgen-deprivation therapy plus apalutamide |
| Publication date | June 2026 |
Prostate Cancer Treatment Evolution: From Surgery Alone to Perioperative Combined Therapy
Integration of androgen-deprivation therapy with apalutamide in high-risk localized disease
Source: Nature Medicine, June 2026 | Georgian Medical Journal News
High-Risk Prostate Cancer Demands Earlier Intervention
Prostate cancer remains a leading cause of cancer mortality in men globally, with high-risk disease defined by aggressive pathological features and elevated recurrence potential. According to Nature Medicine‘s June 2026 report, approximately 20-30% of men with localized prostate cancer harbour disease characteristics that warrant intensified treatment beyond surgery alone. Historically, radical prostatectomy has served as the primary curative intent procedure, yet biochemical recurrence—marked by rising prostate-specific antigen (PSA) levels post-operatively—occurs in a substantial proportion of high-risk patients, necessitating salvage radiation therapy or systemic treatment.
The PROTEUS trial addresses this clinical challenge by evaluating whether perioperative medical therapy can reduce recurrence risk when administered in the window before surgical resection. This neoadjuvant approach mirrors successful models in breast and colorectal oncology, where preoperative systemic therapy improves outcomes in aggressive subtypes. The use of both androgen-deprivation therapy and apalutamide—a potent second-generation androgen receptor inhibitor—targets the hormonal drivers of prostate cancer growth from multiple angles, potentially achieving greater disease control before the surgical dissection.
Apalutamide and Androgen Deprivation: A Dual Mechanism Strategy
Apalutamide, an oral androgen receptor antagonist with strong preclinical activity in castration-resistant disease, has demonstrated clinical benefit in earlier prostate cancer stages when combined with standard hormonal therapies. Published evidence shows that apalutamide acts by blocking androgen receptor signalling with high affinity and inhibiting nuclear translocation, preventing cancer cell proliferation even in low-androgen environments. The PROTEUS regimen, as detailed in Nature Medicine (June 2026), combines traditional gonadal suppression via ADT with apalutamide’s receptor-level antagonism, creating redundant blockade of testosterone-driven signalling.
This dual-mechanism approach offers theoretical advantages: ADT reduces circulating testosterone, while apalutamide blocks residual androgen signalling at the cellular level. Some prostate cancer cells express alternative mechanisms of androgen receptor activation—such as ligand-independent pathways or mutation-driven constitutive activity—that single-agent ADT cannot fully suppress. The combination therefore addresses a broader spectrum of tumour heterogeneity within high-risk lesions. The perioperative window—typically 4 to 6 months before prostatectomy—allows sufficient time for drug accumulation and maximum biological effect on the primary tumour microenvironment.
Clinical Implications and Oncology Practice Shift
The PROTEUS trial findings, published in Nature Medicine (June 2026), represent a potential paradigm shift in how urological oncologists and medical oncologists collaborate in high-risk prostate cancer care. Traditionally, medical oncology has entered prostate cancer management after surgical failure or metastatic progression. Perioperative apalutamide plus ADT moves systemic therapy upstream, into the curative-intent surgical setting, mirroring contemporary approaches to locally advanced colorectal and oesophageal cancers. This integration requires coordination between urology, medical oncology, and primary care teams to manage treatment-related adverse effects—including fatigue, hot flushes, and metabolic changes—whilst optimizing surgical candidacy and recovery.
For patients enrolled in PROTEUS, the perioperative regimen likely demanded careful patient selection, with baseline assessments of cardiovascular fitness, bone health, and functional status to ensure safety during hormonal suppression. Toxicity monitoring during the preoperative phase would have been essential to detect cardiac arrhythmias, electrolyte abnormalities, or other serious adverse events that could compromise surgical outcomes. The trial design presumably incorporated stratification by baseline PSA, Gleason grade, and extent of extraprostatic extension to ensure balanced randomization and robust subgroup analysis.
Future Directions and Unanswered Questions
While the PROTEUS trial demonstrates the feasibility and potential efficacy of perioperative apalutamide plus ADT, several clinical and biological questions remain. Long-term oncological outcomes—including biochemical recurrence-free survival, metastasis-free survival, and overall survival at 5 and 10 years—will be critical to establishing this regimen as a new standard. Nature Medicine (June 2026) provides the phase trial data, but prospective randomized controlled trials comparing perioperative combination therapy to surgery plus observation or surgery plus adjuvant radiation will be needed to confirm superiority and identify which patient subsets benefit most.
Additionally, biomarker-driven stratification—using genomic, proteomic, or imaging signatures to predict treatment response—could refine patient selection and minimize unnecessary toxicity in lower-risk patients within the high-risk category. Resistance mechanisms to apalutamide, including androgen receptor splice variants and ligand-independent activation, may emerge in some tumours; characterizing these mechanisms in post-operative specimens could guide future therapeutic innovations. Finally, integration of novel imaging modalities (such as PSMA PET-CT staging) into perioperative trial design may improve detection of occult metastatic disease and refine surgical candidacy criteria.
Perioperative androgen-deprivation therapy combined with apalutamide represents a new treatment pathway for high-risk, localized prostate cancer, potentially reducing biochemical recurrence when administered before radical prostatectomy.
— Nature Medicine, June 2026
What this means
Frequently asked questions
What defines high-risk, localized prostate cancer?
High-risk disease is typically defined by one or more of the following criteria: PSA >20 ng/mL, Gleason grade group 4-5, or clinical stage T3-T4. According to Nature Medicine (June 2026), these patients have a substantial risk of biochemical and clinical recurrence after radical prostatectomy alone, making them candidates for intensified perioperative therapy.
How does apalutamide differ from older androgen-deprivation therapy?
Apalutamide is a second-generation androgen receptor antagonist that provides potent blockade at the receptor level, complementing traditional ADT’s effect on testosterone production. The combination targets prostate cancer via dual mechanisms: hormonal suppression and direct receptor antagonism, potentially overcoming resistance mechanisms that emerge with single-agent ADT alone, as detailed in perioperative oncology literature and Nature Medicine‘s PROTEUS analysis.
What are the main side effects of perioperative ADT plus apalutamide?
Common adverse effects of combined androgen deprivation and apalutamide include fatigue, hot flushes, decreased libido, metabolic changes (weight gain, lipid elevation), and potential cardiovascular or electrolyte disturbances. These require active management and baseline screening before therapy initiation. The PROTEUS trial, reported in Nature Medicine (June 2026), provides toxicity data and safety monitoring strategies for the perioperative period.
The PROTEUS trial marks a significant step toward earlier, more aggressive intervention in high-risk prostate cancer, embedding systemic medical oncology into the curative surgical pathway. As follow-up data mature and long-term efficacy is confirmed, perioperative apalutamide plus ADT may soon become standard practice for appropriately selected men, reducing recurrence and improving survival outcomes. Ongoing research into biomarker-driven patient selection and resistance mechanisms will further personalize this approach and maximize benefit whilst minimizing harm. For urology and medical oncology communities globally, PROTEUS exemplifies the power of interdisciplinary collaboration in refining cancer care standards.
Source: PROTEUS trial heralds perioperative therapy for prostate cancer, Nature Medicine
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Editorial standards. This article was produced under the GMJ News editorial process, with oversight by the GMJ Editorial Board. Our editorial process. Spotted an error? Contact the editorial team.
